Warner Pharmaceuticals: The Phase I clinical trial of ZG-002 tablets for root medicine research and development has been completed.

Warner Pharmaceutical Announcement: The company’s equity affiliate, Zegen Medical, has completed Phase I clinical trials of ZG-002 tablets. ZG-002 is a novel drug with a completely new structure designed to treat autoimmune diseases, intended for moderate to severe plaque psoriasis. Clinical trial results show that ZG-002 tablets are safe and well tolerated within the explored dose range after single and multiple administrations, with no serious adverse events reported. The pharmacokinetic characteristics are clear and well defined, with blood drug concentrations and exposure levels increasing with the dose. The trial results also indicate that IFN-γ levels decrease as drug exposure increases, suggesting that ZG-002 may have therapeutic potential for moderate to severe psoriasis.